Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered vaccines this population. We carried out a Phase I trial evaluate safety and delivered UK LTBI (NCT02532036). Two volunteers were recruited, well-tolerated no concerns. Aerosolised vaccination induced mycobacterium- vector-specific IFN-γ blood mycobacterium-specific Th1 cytokines bronchoalveolar lavage. identified several important barriers that could hamper recruitment into clinical trials patient did not show any concerns delivery viral-vectored two Mycobacterium (M.tb) infection. It also systemically mucosally demonstrated inducible immune responses following vaccination. A further country higher incidence would confirm these findings.